Anteris Technologies Files 8-K on Corporate Matters
Ticker: AVR · Form: 8-K · Filed: Sep 29, 2025 · CIK: 2011514
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Anteris Tech filed an 8-K on 9/29/25 covering shareholder votes and other key corporate events.
AI Summary
Anteris Technologies Global Corp. filed an 8-K on September 29, 2025, reporting on matters submitted to a vote of security holders and other events. The filing details the company's corporate structure, including its incorporation in Delaware and principal executive offices located in Eagan, MN, and Toowong, Australia.
Why It Matters
This 8-K filing provides updates on significant corporate events and votes, which are crucial for investors to understand the company's governance and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate financial risks or significant negative news.
Key Numbers
- 001-42437 — SEC File Number (Identifies the company's filing with the SEC.)
- 2025-09-29 — Report Date (Date of the earliest event reported in the 8-K.)
Key Players & Entities
- Anteris Technologies Global Corp. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Eagan, MN (location) — Business Address
- Toowong, QLD Australia (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item of information, but the specific details of these matters are not provided in the excerpt.
What 'Other Events' are reported in this 8-K?
The filing lists 'Other Events' as an item of information, but the specific nature of these events is not detailed in the provided text.
When was Anteris Technologies Global Corp. incorporated?
The company is incorporated in Delaware, as stated in the filing.
What is the company's principal executive office address?
The principal executive offices are located at Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD Australia 4066.
What is the SIC code for Anteris Technologies Global Corp.?
The Standard Industrial Classification (SIC) code is 3842, which corresponds to 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES'.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-09-29 11:00:03
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AVR The Nasdaq Global Mar
Filing Documents
- ef20054947_8k.htm (8-K) — 36KB
- 0001140361-25-036430.txt ( ) — 168KB
- avr-20250929.xsd (EX-101.SCH) — 4KB
- avr-20250929_lab.xml (EX-101.LAB) — 22KB
- avr-20250929_pre.xml (EX-101.PRE) — 16KB
- ef20054947_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders On September 29, 2025, Anteris Technologies Global Corp. (the "Company") held a special meeting of its stockholders (the "Special Meeting") at which a quorum was present. The matters listed below were submitted to a vote of the Company's stockholders at the Special Meeting through the solicitation of proxies. Detailed descriptions of the proposals are included in the Company's definitive proxy A total of 18,687,740 shares of the Company's common stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 51.8% of the shares of common stock outstanding as of August 11, 2025, which was the record date for the Special Meeting. Proposal 1. The ASX Waiver Proposal The Company's stockholders approved ASX Limited's grant to the Company of a waiver from Australian Securities Exchange Listing Rule 7.1 to permit the Company to issue new securities without obtaining the approval of the Company's stockholders under ASX Listing Rule 7.1, and otherwise on the terms and conditions summarized in the Proxy Statement (the "ASX Waiver Proposal"). The final voting results are as follows: Votes For Votes Against Abstentions 13,655,466 2,601,191 2,431,083 Proposal 2. The Adjournment Proposal In connection with the Special Meeting, the Company's stockholders approved the proposal to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the ASX Waiver Proposal. No adjournment was necessary as Proposal 1 was approved. The final voting results are as follows: Votes For Votes Against Abstentions 13,762,610 2,461,912 2,463,218
01
Item 8.01 Other Events PARADIGM Trial Update Patient enrollment in the Company's global pivotal registration trial (the "PARADIGM Trial"), initially expected in the third quarter 2025, is now anticipated to commence in the fourth quarter 2025. Following the Investigational Device Exemption ("IDE") review, the Federal Drug Administration ("FDA") requested additional information, primarily related to bench testing, which the Company has now addressed in a formal response. The IDE submission incorporates both the clinical study protocol and the underlying technology package, which demonstrates the DurAVR THV System has been appropriately developed and tested for use in the global pivotal trial. In parallel, regulatory submissions to competent authorities in Europe are underway, highlighting the Company's commitment to advancing the PARADIGM Trial across multiple regions.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anteris Technologies Global Corp. Date: September 29, 2025 By: /s/ Wayne Paterson Name: Wayne Paterson Title: Vice Chairman and Chief Executive Officer